TheraMe! a medtech spinoff from EPFL is at the forefront of advancing cancer treatment. TheraMe! AG was founded in 2023 with a successful seed round. Our journey is rooted in over a decade of academic research conducted in collaboration with a multinational consortium. This solid foundation drives our commitment to revolutionize cancer therapy through state-of-the-art microfluidic technology.

Internationally renowned experts and university professors in the fields of microfluidics, bioinformatics and clinical oncology work together at TheraMe!, having a single goal in mind: Identifying the very best treatment option for any cancer patient, at any stage of the disease! .

Our mission to redefine cancer care. At TheraMe!, we're not just advancing medicine, we're transforming lives.

TheraMe!

Org chart

Teams

Offices